Your browser doesn't support javascript.
Laboratory Testing Implications of Risk-Stratification and Management of COVID-19 Patients.
Liu, Caidong; Wang, Ziyu; Wu, Wei; Xiang, Changgang; Wu, Lingxiang; Li, Jie; Hou, Weiye; Sun, Huiling; Wang, Youli; Nie, Zhenling; Gao, Yingdong; Zhang, Ruisheng; Tang, Haixia; Wang, Qianghu; Li, Kening; Xia, Xinyi; Li, Pengping; Wang, Shukui.
  • Liu C; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Wang Z; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Wu W; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Xiang C; Department of Laboratory Medicine, First People's Hospital of Jiangxia District of Wuhan, Wuhan, China.
  • Wu L; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Li J; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Hou W; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Sun H; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Wang Y; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Nie Z; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Gao Y; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Zhang R; Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Tang H; Department of Critical Care Medicine, Luan Hospital of Chinese Medicine, Lu'an, China.
  • Wang Q; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Li K; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.
  • Xia X; Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing, China.
  • Li P; Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
  • Wang S; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.
Front Med (Lausanne) ; 8: 699706, 2021.
Article in English | MEDLINE | ID: covidwho-1394781
ABSTRACT

Objective:

To distinguish COVID-19 patients and non-COVID-19 viral pneumonia patients and classify COVID-19 patients into low-risk and high-risk at admission by laboratory indicators. Materials and

methods:

In this retrospective cohort, a total of 3,563 COVID-19 patients and 118 non-COVID-19 pneumonia patients were included. There are two cohorts of COVID-19 patients, including 548 patients in the training dataset, and 3,015 patients in the testing dataset. Laboratory indicators were measured during hospitalization for all patients. Based on laboratory indicators, we used the support vector machine and joint random sampling to risk stratification for COVID-19 patients at admission. Based on laboratory indicators detected within the 1st week after admission, we used logistic regression and joint random sampling to develop the survival mode. The laboratory indicators of COVID-10 and non-COVID-19 were also compared.

Results:

We first identified the significant laboratory indicators related to the severity of COVID-19 in the training dataset. Neutrophils percentage, lymphocytes percentage, creatinine, and blood urea nitrogen with AUC >0.7 were included in the model. These indicators were further used to build a support vector machine model to classify patients into low-risk and high-risk at admission in the testing dataset. Results showed that this model could stratify the patients in the testing dataset effectively (AUC = 0.89). Our model still has good performance at different times (Mean AUC 0.71, 0.72, 0.72, respectively for 3, 5, and 7 days after admission). Moreover, laboratory indicators detected within the 1st week after admission were able to estimate the probability of death (AUC = 0.95). We identified six indicators with permutation p < 0.05, including eosinophil percentage (p = 0.007), white blood cell count (p = 0.045), albumin (p = 0.041), aspartate transaminase (p = 0.043), lactate dehydrogenase (p = 0.002), and hemoglobin (p = 0.031). We could diagnose COVID-19 and differentiate it from other kinds of viral pneumonia based on these laboratory indicators.

Conclusions:

Our risk-stratification model based on laboratory indicators could help to diagnose, monitor, and predict severity at an early stage of COVID-19. In addition, laboratory findings could be used to distinguish COVID-19 and non-COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.699706

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.699706